Abstract: Disclosed is a process for preparing new crystal salt forms of sulfasalazine, in particular a crystal Form A of the D(?)-N-methylglucamine (meglumine) salt of sulfasalazine, a crystal form A of the piperazine salt of sulfasalazine and a crystal Form B of the diethylamine salt of sulfasalazine, and the use thereof in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and/or the gastro-intestinal tract.

Abstract: A transfer device (10) for removing or transferring a medium out of or into a bottle (20) having a bottle neck (34) that can be closed by means of a closure (42), including a first adapter part (12), which can be positioned on the bottle, and a second adapter part (14), which interacts with the first adapter part, which can be displaced in the longitudinal direction of the bottle, and has a conducting element (50) for piercing the closure. After the second adapter part (14) has been displaced along the first adapter part in the direction of the closure (42) and the second adapter part has been locked, the first adapter part (12) is non-releasably fastened to or around the bottle (20).

Abstract: A transfer device (10) for removing or transferring a medium out of or into a bottle (20) having a bottle neck (34) that can be closed by means of a closure (42), including a first adapter part (12), which can be positioned on the bottle, and a second adapter part (14), which interacts with the first adapter part, which can be displaced in the longitudinal direction of the bottle, and has a conducting element (50) for piercing the closure. After the second adapter part (14) has been displaced along the first adapter part in the direction of the closure (42) and the second adapter part has been locked, the first adapter part (12) is non-releasably fastened to or around the bottle (20).

Abstract: A transfer device (10) for removing or transferring a medium out of or into a bottle (20) having a bottle neck (34) that can be closed by means of a closure (42), including a first adapter part (12), which can be positioned on the bottle, and a second adapter part (14), which interacts with the first adapter part, which can be displaced in the longitudinal direction of the bottle, and has a conducting element (50) for piercing the closure. After the second adapter part (14) has been displaced along the first adapter part in the direction of the closure (42) and the second adapter part has been locked, the first adapter part (12) is non-releasably fastened to or around the bottle (20).

Abstract: A process is described for the preparation of freeze-dried pharmaceutical compositions of mitomycin C, which are characterized by high stability and can be rapidly reconstituted to form solutions.

Abstract: A method for purifying epidaunorubicin is provided. The purification method involves the removal of the impurity epi-feudomycin, which is formed as a by-product in the biotechnological production of epidaunorubicin.

Abstract: A crystalline epirubicin hydrochloride and a method for its production are provided. The method for producing the crystalline epirubicin hydrochloride includes the steps: (a) providing epirubicin hydrochloride, (b) producing a mixture containing the provided epirubicin hydrochloride and at least one alcohol selected from the group 1-butanol, 2-butanol, and 1-pentanol, and (c) crystallizing epirubicin hydrochloride from this mixture.

Abstract: 4?-epidaunorubicin hydrochloride is provided in a crystalline form which is stable and readily soluble. A process of producing the crystalline form includes crystallizing 4?-epidaunorubicin hydrochloride in a solvent system including (a) solvent A selected from C1 and C2 halogenated solvents and mixtures thereof, (b) solvent B selected from C1-C5 straight and branched alcohols and mixtures thereof, and (c) solvent C selected from C1-C5 straight and branched alcohols and mixtures thereof, wherein solvent C is selected to provide lower solubility to 4?-epidaunorubicin hydrochloride than solvent B. A method of producing an anthracycline using crystalline 4?-epidaunorubicin hydrochloride is also provided.

Abstract: Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml. The invention also relates to a ready-made syringe and a carpule containing such a pharmaceutical solution formulation, as well as a pen injector comprising such a carpule and/or a ready-made syringe.

Abstract: Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml. The invention also relates to a ready-made syringe and a carpule containing such a pharmaceutical solution formulation, as well as a pen injector comprising such a carpule and/or a ready-made syringe.